{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:04:36Z","timestamp":1780416276407,"version":"3.54.1"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016419","name":"Breast Cancer Research Foundation of Alabama","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016419","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UAB O\u2019Neal Comprehensive Cancer Center O\u2019Neal Invests","award":["P30CA013148"],"award-info":[{"award-number":["P30CA013148"]}]},{"name":"Community Foundation of Greater Birmingham Women\u2019s Breast Health Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical trial participants rarely represent the real-world treatment population, potentially due to costs associated with participation. Monetary reimbursement for trial-related costs could address financial barriers to trial recruitment and retention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This mixed-methods, pilot, feasibility study provided financial reimbursement to women with breast cancer participating in a clinical trial. Patients were reimbursed $1000\/month during their first 4 months of trial participation, surveyed biweekly to assess changes in financial toxicity, and then interviewed to explore the effects of receiving reimbursement on trial-related costs and recruitment and retention. Mixed-effect modeling and thematic analysis were completed. Feasibility was defined as 80% retention of patients on the reimbursement study, with those retained completing 75% of surveys.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 39 consented patients, 33 patients completed the pilot study (85% retention, 100% survey completion). Patients were a median 52\u2009years old (interquartile range = 44-59), 48% Black, 67% privately insured, and 42% found it difficult to live on their current income. Patient financial toxicity modestly decreased. Patients (n\u2009=\u200932) reported using the reimbursement to pay for trial visit-related food, transportation, caregiver expenses, and out-of-pocket medical costs. Patients felt receiving reimbursement affected trial retention more so than recruitment, stating \u201cI would have enrolled regardless \u2026 [but knowing] it wasn\u2019t going to place a financial strain on us because of these reimbursements. \u2026 It made it easier for me to feel good about continuing.\u201d<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Reimbursement for clinical trial-related costs is feasible, suggests decreases in financial toxicity, and is a promising approach to improve trial retention outcomes in women with breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov ID<\/jats:title>\n                    <jats:p>NCT05871125<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jncics\/pkag048","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:10:56Z","timestamp":1777637456000},"source":"Crossref","is-referenced-by-count":0,"title":["Financial reimbursement for clinical trial participation costs: a pilot feasibility study"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5328-7517","authenticated-orcid":false,"given":"Courtney P","family":"Williams","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine & Population Science, University of Alabama at Birmingham , Birmingham, AL,","place":["United States"]},{"name":"O\u2019Neal Comprehensive Cancer Center, University of Alabama at Birmingham , Birmingham, AL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2101-3065","authenticated-orcid":false,"given":"Nicole L","family":"Henderson","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center, University of Alabama at Birmingham , Birmingham, AL,","place":["United States"]},{"name":"Division of Hematology & Oncology, University of Alabama at Birmingham , Birmingham, AL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9311-0780","authenticated-orcid":false,"given":"Nusrat","family":"Jahan","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, University of Alabama at Birmingham , Birmingham, AL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Stringer-Reasor","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, University of Alabama at Birmingham , Birmingham, AL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9883-1424","authenticated-orcid":false,"given":"Andres","family":"Azuero","sequence":"additional","affiliation":[{"name":"School of Nursing, University of Alabama at Birmingham , Birmingham, AL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9329-3268","authenticated-orcid":false,"given":"Maria","family":"Pisu","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine & Population Science, University of Alabama at Birmingham , Birmingham, AL,","place":["United States"]},{"name":"O\u2019Neal Comprehensive Cancer Center, University of Alabama at Birmingham , Birmingham, AL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C","family":"Arend","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center, University of Alabama at Birmingham , Birmingham, AL,","place":["United States"]},{"name":"Department of Obstetrics and Gynecology, University of Alabama at Birmingham , Birmingham, AL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4188-9785","authenticated-orcid":false,"given":"Gabrielle B","family":"Rocque","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center, University of Alabama at Birmingham , Birmingham, AL,","place":["United States"]},{"name":"Division of Hematology & Oncology, University of Alabama at Birmingham , Birmingham, AL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,3]]},"reference":[{"key":"2026060211115399300_pkag048-B1","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/jamaoncol.2023.1341","article-title":"Enhancing patient retention in clinical trials\u2014strategies for success","volume":"9","author":"Idossa","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026060211115399300_pkag048-B2","doi-asserted-by":"publisher","first-page":"djv324","DOI":"10.1093\/jnci\/djv324","article-title":"Predicting low accrual in the National Cancer Institute\u2019s cooperative group clinical trials","volume":"108","author":"Bennette","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2026060211115399300_pkag048-B3","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1001\/jamaoncol.2023.1648","article-title":"Rates of and factors associated with patient withdrawal of consent in cancer clinical trials","volume":"9","author":"Hillman","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026060211115399300_pkag048-B4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.apjon.2021.12.015","article-title":"Participation in and withdrawal from cancer clinical trials: a survey of clinical research coordinators","volume":"9","author":"Kim","year":"2022","journal-title":"Asia Pac J Oncol Nurs"},{"key":"2026060211115399300_pkag048-B5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/annonc\/mdh100","article-title":"Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study","volume":"15","author":"Groen","year":"2004","journal-title":"Ann Oncol"},{"key":"2026060211115399300_pkag048-B6","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1200\/JCO.2000.18.6.1212","article-title":"Docetaxel administered on a weekly basis for metastatic breast cancer","volume":"18","author":"Burstein","year":"2000","journal-title":"J Clin Oncol"},{"key":"2026060211115399300_pkag048-B7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/her\/cyl095","article-title":"Recruitment and retention of Latinos in a primary care-based physical activity and diet trial: the resources for health study","volume":"22","author":"Eakin","year":"2007","journal-title":"Health Educ Res"},{"key":"2026060211115399300_pkag048-B8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1177\/0145721705275517","article-title":"Recruitment and retention of rural African Americans in diabetes research: lessons learned","volume":"31","author":"Loftin","year":"2005","journal-title":"Diabetes Educ"},{"key":"2026060211115399300_pkag048-B9","doi-asserted-by":"publisher","first-page":"e2322515\u2013e2322515","DOI":"10.1001\/jamanetworkopen.2023.22515","article-title":"Racial and ethnic inequities in US oncology clinical trial participation from 2017 to 2022","volume":"6","author":"Pittell","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026060211115399300_pkag048-B10","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2012.45.4553","article-title":"Patient income level and cancer clinical trial participation","volume":"31","author":"Unger","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026060211115399300_pkag048-B11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/edbk_100019","article-title":"Financial toxicity and equitable access to clinical trials","volume":"39","author":"Chino","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026060211115399300_pkag048-B12","doi-asserted-by":"publisher","first-page":"djw205","DOI":"10.1093\/jnci\/djw205","article-title":"Financial hardships experienced by cancer survivors: a systematic review","volume":"109","author":"Altice","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"2026060211115399300_pkag048-B13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/1055-9965.Epi-19-0352","article-title":"Insurance coverage, employment status, and financial well-being of young women diagnosed with breast cancer","volume":"29","author":"Tangka","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026060211115399300_pkag048-B14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1200\/jco.19.01564","article-title":"Understanding financial hardship among cancer survivors in the United States: strategies for prevention and mitigation","volume":"38","author":"Yabroff","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026060211115399300_pkag048-B15","author":"Health Insurance Coverage of Clinical Trials","year":"2022"},{"key":"2026060211115399300_pkag048-B16","author":"Insurance Coverage and Clinical Trials","year":"2022"},{"key":"2026060211115399300_pkag048-B17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1200\/JCO.2016.69.9835","article-title":"Access to accredited cancer hospitals within federal exchange plans under the affordable care act","volume":"35","author":"Kehl","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026060211115399300_pkag048-B18","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1634\/theoncologist.2017-0628","article-title":"At what cost to clinical trial enrollment? a retrospective study of patient travel burden in cancer clinical trials","volume":"23","author":"Borno","year":"2018","journal-title":"Oncologist"},{"key":"2026060211115399300_pkag048-B19","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/onco.13767","article-title":"Patient-reported out-of-pocket costs and financial toxicity during early-phase oncology clinical trials","volume":"26","author":"Huey","year":"2021","journal-title":"Oncologist"},{"key":"2026060211115399300_pkag048-B20","doi-asserted-by":"publisher","first-page":"e7185","DOI":"10.1002\/cam4.7185","article-title":"Understanding the financial cost of cancer clinical trial participation","volume":"13","author":"Williams","year":"2024","journal-title":"Cancer Med"},{"key":"2026060211115399300_pkag048-B21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1001\/jamaoncol.2015.3924","article-title":"Patient income level and cancer clinical trial participation: a prospective survey study","volume":"2","author":"Unger","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026060211115399300_pkag048-B22","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s11606-022-07801-0","article-title":"Influence of cost-related considerations on clinical trial participation: results from the 2020 Health Information National Trends Survey (HINTS)","volume":"38","author":"Williams","year":"2023","journal-title":"J Gen Intern Med."},{"key":"2026060211115399300_pkag048-B23","author":"Survivor Views: Telehealth and Clinical Trials","year":"2025"},{"key":"2026060211115399300_pkag048-B24","doi-asserted-by":"publisher","first-page":"100305","DOI":"10.1016\/j.jcpo.2021.100305","article-title":"Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysis","volume":"30","author":"Borno","year":"2021","journal-title":"J Cancer Policy"},{"key":"2026060211115399300_pkag048-B25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1634\/theoncologist.2015-0481","article-title":"Financial burden of cancer clinical trial participation and the impact of a cancer care equity program","volume":"21","author":"Nipp","year":"2016","journal-title":"Oncologist"},{"key":"2026060211115399300_pkag048-B26","first-page":"1","article-title":"Paying research participants: the outsized influence of \u201cundue influence","volume":"39","author":"Largent","year":"2017","journal-title":"IRB"},{"key":"2026060211115399300_pkag048-B27","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/medethics-2018-105140","article-title":"Differential payment to research participants in the same study: an ethical analysis","volume":"45","author":"Persad","year":"2019","journal-title":"J Med Ethics"},{"key":"2026060211115399300_pkag048-B28","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1056\/NEJMsb1710591","article-title":"A framework for ethical payment to research participants","volume":"378","author":"Gelinas","year":"2018","journal-title":"N Engl J Med"},{"key":"2026060211115399300_pkag048-B29","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamaoncol.2018.0492","article-title":"Addressing financial barriers to enrollment in clinical trials","volume":"4","author":"Largent","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026060211115399300_pkag048-B30","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cncr.30369","article-title":"Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST)","volume":"123","author":"de Souza","year":"2017","journal-title":"Cancer"},{"key":"2026060211115399300_pkag048-B31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ygyno.2019.11.022","article-title":"Extensive financial hardship among gynecologic cancer patients starting a new line of therapy","volume":"156","author":"Liang","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2026060211115399300_pkag048-B32","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1097\/mlr.0000000000001910","article-title":"Cancer-related financial hardship screening as part of practice transformation","volume":"61","author":"Williams","year":"2023","journal-title":"Med Care"},{"key":"2026060211115399300_pkag048-B33","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1200\/op.23.00243","article-title":"Financial toxicity and quality of life in patients undergoing stem-cell transplant evaluation: a single-center analysis","volume":"20","author":"Hussaini","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"2026060211115399300_pkag048-B34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2307\/2531628","article-title":"Continual reassessment method: a practical design for phase 1 clinical trials in cancer","volume":"46","author":"O\u2019Quigley","year":"1990","journal-title":"Biometrics"},{"key":"2026060211115399300_pkag048-B35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12874-018-0638-z","article-title":"How to design a dose-finding study using the continual reassessment method","volume":"19","author":"Wheeler","year":"2019","journal-title":"BMC Med Res Methodol."},{"key":"2026060211115399300_pkag048-B36","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1200\/edbk_319783","article-title":"Moving beyond 3\u2009+\u20093: the future of clinical trial design","volume":"41","author":"Kurzrock","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026060211115399300_pkag048-B37","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2026060211115399300_pkag048-B38","doi-asserted-by":"publisher","first-page":"e915","DOI":"10.1200\/op.21.00328","article-title":"Implementation of a multisite financial reimbursement program in cancer clinical trials integrated with patient navigation: a pilot randomized clinical trial","volume":"18","author":"Borno","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"2026060211115399300_pkag048-B39","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1634\/theoncologist.2015-0481","article-title":"Financial burden of cancer clinical trial participation and the impact of a cancer care equity program","volume":"21","author":"Nipp","year":"2016","journal-title":"Oncologist"},{"key":"2026060211115399300_pkag048-B40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13012-017-0635-3","article-title":"Psychometric assessment of three newly developed implementation outcome measures","volume":"12","author":"Weiner","year":"2017","journal-title":"Implement Sci"},{"key":"2026060211115399300_pkag048-B41","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2026060211115399300_pkag048-B42","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2026060211115399300_pkag048-B43","author":"Rural-Urban Continuum Codes United States Department of Agriculture Economic Research Service","year":"2020"},{"key":"2026060211115399300_pkag048-B44","author":"NIH National Center for Complementary and Integrative Health","year":"2020"},{"key":"2026060211115399300_pkag048-B45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/mlr.0000000000001664","article-title":"Guidelines for designing and evaluating feasibility pilot studies","volume":"60","author":"Teresi","year":"2022","journal-title":"Med Care"},{"key":"2026060211115399300_pkag048-B46","doi-asserted-by":"publisher","first-page":"16094069241296206","DOI":"10.1177\/16094069241296206","article-title":"Sample sizes for 10 types of qualitative data analysis: an integrative review, empirical guidance, and next steps","volume":"23","author":"Wutich","year":"2024","journal-title":"Int J Qual Methods"},{"key":"2026060211115399300_pkag048-B47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol Bull"},{"key":"2026060211115399300_pkag048-B48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF00988593","article-title":"Grounded theory research: procedures, canons, and evaluative criteria","volume":"13","author":"Corbin","year":"1990","journal-title":"Qual Sociol"},{"key":"2026060211115399300_pkag048-B49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/EDBK_243729","article-title":"Overcoming barriers to clinical trial enrollment","volume":"39","author":"Nipp","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026060211115399300_pkag048-B50","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1634\/theoncologist.2019-0146","article-title":"Addressing the financial burden of cancer clinical trial participation: longitudinal effects of an equity intervention","volume":"24","author":"Nipp","year":"2019","journal-title":"Oncologist"},{"key":"2026060211115399300_pkag048-B51","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1525\/jer.2011.6.3.31","article-title":"Perceptions of reimbursement for clinical trial participation","volume":"6","author":"Breitkopf","year":"2011","journal-title":"J Empir Res Hum Res Ethics"},{"key":"2026060211115399300_pkag048-B52","author":"Payment and Reimbursement to Research Subjects","year":"2022"},{"key":"2026060211115399300_pkag048-B53","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1200\/JCO.18.01132","article-title":"Addressing financial barriers to patient participation in clinical trials: ASCO policy statement","volume":"36","author":"Winkfield","year":"2018","journal-title":"JCO"},{"key":"2026060211115399300_pkag048-B54","doi-asserted-by":"publisher","first-page":"106740","DOI":"10.1016\/j.cct.2022.106740","article-title":"Inclusion and diversity in clinical trials: Actionable steps to drive lasting change","volume":"116","author":"Kelsey","year":"2022","journal-title":"Contemp Clin Trials"},{"key":"2026060211115399300_pkag048-B55","author":"Allowable Costs to Improve Human Subjects Participation and Inclusion","year":"2024"},{"key":"2026060211115399300_pkag048-B56","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1200\/jco.24.00843","article-title":"Patient enrollment to industry-sponsored versus federally-sponsored cancer clinical trials","volume":"42","author":"Unger","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026060211115399300_pkag048-B57","author":"Clinical Trial Modernization Act, H.R.3521, House of Representatives (Rep. Ruiz R 2025","year":"2025"},{"key":"2026060211115399300_pkag048-B58","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1001\/jamainternmed.2018.3931","article-title":"Estimated costs of pivotal trials for novel therapeutic agents approved by the US food and drug administration, 2015-2016","volume":"178","author":"Moore","year":"2018","journal-title":"JAMA Intern Med"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkag048\/68207098\/pkag048.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/10\/3\/pkag048\/68207098\/pkag048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/10\/3\/pkag048\/68207098\/pkag048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:12:01Z","timestamp":1780413121000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkag048\/8666875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkag048","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,3]]},"article-number":"pkag048"}}